Cargando…

Ipilimumab: A tale of twists and turns

Detalles Bibliográficos
Autor principal:	Abhyankar, Dhiraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	ORIGINAL ARTICLE: Immuno - Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069333/ https://www.ncbi.nlm.nih.gov/pubmed/30112338 http://dx.doi.org/10.4103/sajc.sajc_231_17

Ejemplares similares

Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report from a Major Tertiary Care Center
por: Farha, Natalie, et al.
Publicado: (2023)

Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study
por: Tiu, Bruce C, et al.
Publicado: (2023)

PD‐L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study
por: Khattak, Muhammad A., et al.
Publicado: (2019)

The Inconsistent and Inadequate Reporting Of Immune‐Related Adverse Events in PD‐1/PD‐L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials
por: Xie, Tong, et al.
Publicado: (2021)

Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019)

Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer
por: Akamatsu, Hiroaki, et al.
Publicado: (2019)

Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy
por: Bilen, Mehmet Asim, et al.
Publicado: (2019)

Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
por: Chang, Elaine, et al.
Publicado: (2021)

Humoral Immune Response of SARS‐CoV‐2–Infected Patients with Cancer: Influencing Factors and Mechanisms
por: Esperança‐Martins, Miguel, et al.
Publicado: (2021)

Analysis of Real‐World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death‐1 and Programmed Cell Death‐Ligand 1 Inhibitors in Advanced Non‐Small Cell Lung Cancers
por: Ayers, Kristin L., et al.
Publicado: (2021)

Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection
por: Alkrekshi, Akram, et al.
Publicado: (2021)

Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer
por: Chen, Ruifeng, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology
por: Choucair, Khalil, et al.
Publicado: (2022)

Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials
por: Wei, Xiao-Li, et al.
Publicado: (2022)

Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers
por: Morris, Van K, et al.
Publicado: (2023)

Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors
por: Silverstein, Jordyn, et al.
Publicado: (2023)

Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung Cancer
por: Wei, Yuanfeng, et al.
Publicado: (2023)

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience
por: Nardo, Mirella, et al.
Publicado: (2023)

Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events
por: Mathias, Kristen, et al.
Publicado: (2023)

Unusual presentation of parasitic leiomyoma; a tale of twists and turns
por: Shaukat, Irfan, et al.
Publicado: (2019)

Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy
por: Gupta, Vineet Govinda, et al.
Publicado: (2019)

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Full of twists and turns: Collecting duct carcinoma presenting as persistent cough
por: Li, Xueying, et al.
Publicado: (2022)

Twists and turns
por: Noël, Emily S, et al.
Publicado: (2017)

A Tertiary Twist to the Transglutaminase Tale
por: Koning, Frits
Publicado: (2007)

A Twisting Tale of Infective Endocarditis
por: Akram, Abeera, et al.
Publicado: (2019)

Research and leaders: a twisted tale!
por: Prasad, Ashish, et al.
Publicado: (2021)

Intratumoral Immunotherapy—Update 2019
por: Hamid, Omid, et al.
Publicado: (2019)

SecA—a New Twist in the Tale
por: Collinson, Ian
Publicado: (2016)

Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study
por: Giunta, Alessandro, et al.
Publicado: (2016)

The genetics of dystonia: new twists in an old tale
por: Charlesworth, Gavin, et al.
Publicado: (2013)

Suicide risk and psychiatric comorbidity in patients with psoriasis
por: Pompili, Maurizio, et al.
Publicado: (2016)

Long-term safety of etanercept in psoriasis: Retrospective study focused on infections
por: Orsini, Diego, et al.
Publicado: (2016)

Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports
por: De Simone, Clara, et al.
Publicado: (2016)

CTLA-4 and Autoimmunity: New Twists in the Tale
por: Walker, Lucy S.K.
Publicado: (2015)

Twists or turns: stabilising alpha vs. beta turns in tetrapeptides
por: Hoang, Huy N., et al.
Publicado: (2019)

Rickets: Twists and turns in the Gordian knot
por: Garg, M. K., et al.
Publicado: (2013)

An Unusual Eyelid Mass of Cysticercosis: A Twist in the Tale
por: Rai, Poonam J, et al.
Publicado: (2016)

Ipilimumab as a Cause of Severe Pan-Colitis and Colonic Perforation
por: Shah, Raj, et al.
Publicado: (2017)

“An antibiotic turned contraceptive”: The tale of ampicillin‐cloxacillin
por: Iheanacho, Chinonyerem O.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p3kh2njlmnthnuf5u49l45abpt